Table 1.
Characteristics of Hong Kong cohort
| Hong Kong cohort (n = 1,315), n (%) | NLR, n (%) |
p value | PLR, n (%) |
p value | PNI, n (%) |
p value | SII, n (%) |
p value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <5(n = 1,043) | ≥5(n = 272) | ≤150 (n = 826) | ≥150 (n = 489) | ≥45(n = 717) | <45(n = 598) | <330 (n = 457) | ≥330 (n = 860) | ||||||
| Patient factors | |||||||||||||
| Gender, male | 1,140 (86.7) | 902 (86.5) | 238 (87.5) | 0.660 | 713 (86.3) | 427 (87.3) | 0.605 | 626 (87.3) | 514 (86.0) | 0.471 | 385 (84.4) | 755 (87.9) | 0.078 |
| Age, years, mean ± SD | 59.2±11.2 | 59.2±11.2 | 59.2±11.5 | 0.988 | 59.7±10.5 | 58.4±12.4 | 0.045 | 58.1±10.9 | 60.6±11.4 | <0.001 | 60.3±10.2 | 58.7±11.7 | 0.012 |
| Etiology | |||||||||||||
| Hepatitis B | 1,060 (80.6) | 843 (80.8) | 217 (79.8) | 0.698 | 679 (82.2) | 381 (77.9) | 0.057 | 577 (80.5) | 483 (80.8) | 0.893 | 373 (81.8) | 687 (80.0) | 0.427 |
| Hepatitis C | 86 (6.5) | 78 (7.5) | 8 (2.9) | 0.007 | 72 (8.7) | 14 (2.9) | <0.001 | 45 (6.3) | 41 (6.9) | 0.672 | 49 (10.7) | 37 (4.3) | <0.001 |
| Hepatitis B & C | 7 (0.5) | 4 (0.4) | 3 (1.1) | 0.159 | 3 (0.4) | 4 (0.8) | 0.435 | 1 (0.1) | 6 (1.0) | 0.052 | 3 (0.7) | 4 (0.5) | 0.699 |
| Non-B/Non-C | 162 (12.3) | 118 (11.3) | 44 (16.2) | 0.030 | 72 (8.7) | 90 (18.4) | <0.001 | 94 (13.1) | 68 (11.4) | 0.339 | 31 (6.8) | 131 (15.3) | <0.001 |
| Child-Pugh grade | 0.036 | ||||||||||||
| A | 1,097 (83.4) | 937 (89.8) | 160 (58.8) | 729 (88.3) | 368 (75.3) | 708 (98.7) | 389 (65.1) | 396 (86.8) | 701 (81.6) | ||||
| B | 197 (15.0) | 99 (9.5) | 98 (36.0) | 89 (10.8) | 108 (22.1) | 9 (1.3) | 188 (31.4) | 56 (12.3) | 141 (16.4) | ||||
| C | 21 (1.6) | 7 (0.7) | 14 (5.1) | 8 (1.0) | 13 (2.7) | 0(0) | 21 (3.5) | 4(0.9) | 17 (2.0) | ||||
| ALBI grade | <0.001 | <0.001 | <0.001 | 0.257 | |||||||||
| 1 | 622 (47.3) | 574 (55.0) | 48 (17.6) | 442 (53.5) | 180 (36.8) | 569 (79.4) | 389 (65.1) | 229 (50.2) | 393 (45.8) | ||||
| 2 | 619 (47.1) | 437 (41.9) | 182 (66.9) | 345 (41.8) | 274 (56.0) | 148 (20.6) | 188 (31.4) | 205 (45.0) | 414 (48.2) | ||||
| 3 | 74 (5.6) | 32 (3.1) | 42 (15.4) | 39 (4.7) | 35 (7.2) | 0(0) | 21 (3.5) | 22 (4.8) | 52 (6.1) | ||||
| Performance status >0 | 337 (25.6) | 195 (18.7) | 142 (52.2) | <0.001 | 128 (15.5) | 209 (42.7) | <0.001 | 105 (14.6) | 232 (38.8) | <0.001 | 50 (11.0) | 287 (33.4) | <0.001 |
| Tumor characteristics | |||||||||||||
| Tumor size, mm, | |||||||||||||
| median (IQR) | 51 (30–95) | 45 (27–80) | 90 (48–136) | <0.001 | 40 (25–68) | 92 (50–130) | <0.001 | 43 (26–80) | 65 (35–110) | <0.001 | 35 (25–52) | 70 (35–112) | <0.001 |
| Multiple tumors | 585 (44.5) | 422 (40.4) | 163 (59.7) | <0.001 | 313 (37.9) | 272 (55.6) | <0.001 | 266 (37.1) | 319 (53.3) | <0.001 | 176 (38.6) | 409 (47.6) | 0.002 |
| Vascular invasion | 263 (20.0) | 156 (14.9) | 108 (39.6) | <0.001 | 112 (13.6) | 151 (30.9) | <0.001 | 95 (13.2) | 168 (28.1) | <0.001 | 49 (10.7) | 214 (24.9) | <0.001 |
| Extrahepatic spread | 159 (12.1) | 78 (7.5) | 81 (29.8) | <0.001 | 50 (6.1) | 109 (22.3) | <0.001 | 48 (6.7) | 111 (18.6) | <0.001 | 17 (3.7) | 142 (16.5) | <0.001 |
| BCLC stage | <0.001 | <0.001 | <0.001 | ||||||||||
| 0 | 73 (5.6) | 66 (6.3) | 7 (2.6) | 61 (7.4) | 12 (2.5) | 51 (7.1) | 22 (3.7) | 39 (8.6) | 34 (4.0) | ||||
| A | 533 (40.5) | 480 (46.0) | 54 (19.8) | 404 (48.9) | 129 (26.4) | 361 (50.3) | 172 (28.8) | 228 (50.0) | 305 (35.5) | ||||
| B | 237 (18.0) | 197 (18.9) | 40 (14.7) | 150 (18.2) | 87 (17.8) | 132 (18.4) | 105 (17.6) | 95 (20.8) | 142 (16.5) | ||||
| C | 425 (32.3) | 284 (27.2) | 142 (52.0) | 194 (23.5) | 231 (47.2) | 172 (24.0) | 253 (42.3) | 87 (19.1) | 338 (39.3) | ||||
| D | 47 (3.6) | 17 (1.6) | 30 (11.0) | 17 (2.1) | 30 (6.1) | 4 (0.6) | 67 (11.2) | 7 (1.5) | 40 (4.7) | ||||
| Serum AFP, µg/L, median (IQR) | 90 (8–1,860) | 60 (7–772) | 898 (39–23,470) | <0.001 | 48 (8–484) | 429 (13–16,730) | <0.001 | 47 (6–748) 178 (15–4,318) | <0.001 | 38 (9–343) 169 (8–4,385) | <0.001 | ||
| Treatment modality | <0.001 | <0.001 | <0.001 | <0.001 | |||||||||
| Surgical resection | 538 (40.9) | 485 (46.5) | 55 (20.1) | 392 (47.5) | 146 (29.9) | 388 (54.1) | 150 (25.1) | 198 (43.4) | 340 (39.6) | ||||
| Local ablative therapy | 128 (9.7) | 114 (10.9) | 14 (5.1) | 115 (13.9) | 13 (2.7) | 79 (11.0) | 49 (8.2) | 83 (18.2) | 45 (5.2) | ||||
| Transarterial therapy | 318 (24.2) | 256 (24.5) | 62 (22.7) | 195 (23.6) | 123 (25.2) | 142 (19.8) | 176 (29.4) | 124 (27.2) | 194 (22.6) | ||||
| Systemic agent | 122 (9.3) | 80 (7.7) | 42 (15.4) | 39 (4.7) | 83 (17.0) | 60 (8.4) | 62 (10.4) | 14 (3.1) | 108 (12.6) | ||||
| Best supportive care | 209 (15.9) | 109 (10.4) | 100 (36.6) | 85 (10.3) | 124 (25.4) | 48 (6.7) | 161 (26.9) | 37 (8.1) | 172 (20.0) | ||||
AFP, alpha-fetoprotein; ALBI, albumin-bilirubin score; BCLC, Barcelona Clinic Liver Cancer; IQR, interquartile range; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index.